argenx SE header image

argenx SE

ARGX

Equity

ISIN NL0010832176 / Valor 24766616

Euronext - Euronext Brussels (2026-07-30)

EUR 746.60-3.74%

argenx SE
UMushroom community rating:

4.86 3 votes No rating yet

NegativeNeutralPositive

About company

Argenx SE is a biotechnology company that specializes in developing innovative therapies for the treatment of severe autoimmune diseases and cancer. The company leverages its proprietary technology platform to create a portfolio of first-in-class product candidates, which are developed in collaboration with academic partners. Argenx's approach focuses on translating breakthroughs in immunology into effective medicines, aiming to address unmet medical needs. The company's flagship product, efgartigimod, is designed to modulate the immune system and is being explored for multiple autoimmune indications. Argenx is headquartered in the Netherlands and operates globally, with a commitment to advancing its pipeline through rigorous research and development efforts.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

42.7%1Y

64.4%3Y

190%5Y

Performance

33.4%1Y

37.6%3Y

38.5%5Y

Volatility

53750 M

Market cap (USD)

97,191

Daily traded volume (Shares)

600 / 594.2

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.86

3 votes

Performance:

4.71

Innovation:

5.00

Society:

4.86

Nature:

3.57

Laura Sofie Tohver

UK, 11 Nov 2025

Emerging technology and nice returns

Viktor Stockel

Switzerland, 30 Oct 2025

Argenx SE is a commercial-stage, global biopharmaceutical company focused on immunology, particularly therapies for severe autoimmune diseases.

Claudia Stadelmann

Switzerland, 05 Mar 2025

Geheimtipp belgisches Biotech mit spannender Pipeline

EQUITIES OF THE SAME SECTOR

ecotel communication ag

ecotel communication ag Valor: 2489718

Annual Return

-50%0%+50%

Risk level

110

0.00%EUR 7.10

Evolution AB

Evolution AB Valor: 48025470

Annual Return

-50%0%+50%

Risk level

110

-1.86%SEK 737.20

Qualys Inc

Qualys Inc Valor: 19549949

Annual Return

-50%0%+50%

Risk level

110

4.87%USD 141.71

Tarsus Pharmaceuticals Inc

Tarsus Pharmaceuticals Inc Valor: 57410241

Annual Return

-50%0%+50%

Risk level

110

-0.73%USD 58.52

AECOM

AECOM Valor: 2986443

Annual Return

-50%0%+50%

Risk level

110

-2.46%USD 71.76

Koninklijke Philips NV

Koninklijke Philips NV Valor: 1106818

Annual Return

-50%0%+50%

Risk level

110

0.35%EUR 22.88

Mycronic AB

Mycronic AB Valor: 659217

Annual Return

-50%0%+50%

Risk level

110

1.29%SEK 313.80

HMS Networks AB

HMS Networks AB Valor: 36954778

Annual Return

-50%0%+50%

Risk level

110

1.59%SEK 485.00

Addnode Group AB

Addnode Group AB Valor: 119004945

Annual Return

-50%0%+50%

Risk level

110

-4.09%SEK 38.70

Agilysys Inc

Agilysys Inc Valor: 1680840

Annual Return

-50%0%+50%

Risk level

110

-5.31%USD 107.65

SIX

FactSet

Clearbit

Logos provided by Clearbit